The Adhesion GPCR VLGR1/ADGRV1 Regulates the Ca2+ Homeostasis at Mitochondria-Associated ER Membranes

Cells. 2022 Sep 7;11(18):2790. doi: 10.3390/cells11182790.

Abstract

The very large G protein-coupled receptor (VLGR1, ADGRV1) is the largest member of the adhesion GPCR family. Mutations in VLGR1 have been associated with the human Usher syndrome (USH), the most common form of inherited deaf-blindness as well as childhood absence epilepsy. VLGR1 was previously found as membrane-membrane adhesion complexes and focal adhesions. Affinity proteomics revealed that in the interactome of VLGR1, molecules are enriched that are associated with both the ER and mitochondria, as well as mitochondria-associated ER membranes (MAMs), a compartment at the contact sites of both organelles. We confirmed the interaction of VLGR1 with key proteins of MAMs by pull-down assays in vitro complemented by in situ proximity ligation assays in cells. Immunocytochemistry by light and electron microscopy demonstrated the localization of VLGR1 in MAMs. The absence of VLGR1 in tissues and cells derived from VLGR1-deficient mouse models resulted in alterations in the MAM architecture and in the dysregulation of the Ca2+ transient from ER to mitochondria. Our data demonstrate the molecular and functional interaction of VLGR1 with components in MAMs and point to an essential role of VLGR1 in the regulation of Ca2+ homeostasis, one of the key functions of MAMs.

Keywords: Ca2+ homeostasis; Ca2+ transient at ER and mitochondria; adhesion GPCR; mitochondria-associated ER membranes (MAM); mitochondria-endoplasmic reticulum contact sites (MERCS).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Child
  • Endoplasmic Reticulum* / metabolism
  • Homeostasis
  • Humans
  • Mice
  • Mitochondria / metabolism
  • Mitochondrial Membranes* / metabolism

Grants and funding

This work was supported by: The German Research Council DFG FOR 2149 Elucidation of Adhesion-GPCR Signaling, project number 246212759 (U.W.); The German Research Council DFG SPP SPP2127 - Gene and Cell based therapies to counteract neuroretinal degeneration, project numbers 399443882 (K.N.W.), 399366294 (M.U.), 399487434 (U.W.); The Foundation Fighting Blindness (FFB) PPA-0717-0719-RAD (U.W. and M.U.); and Leibniz-research group project SynERCa-1 (F.M. and M.H.); Tistou and Charlotte Kerstan Foundation (M.U.).